Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Two investigational anti-B7-H3 antibody-drug conjugates (ADCs) have shown significant survival benefits in patients with relapsed small-cell lung cancer (SCLC). According to Medical Xpress, the ARTEMIS-008 trial found that risvutatug rezetecan (Ris-Rez) improved overall survival compared to topotecan in patients whose disease progressed after platinum-based chemotherapy.

The trial involved 461 patients in China who were randomly assigned to receive either Ris-Rez or topotecan. At a median follow-up of 12.2 months, the median overall survival was 18.5 months with Ris-Rez and 10.3 months with topotecan. Ris-Rez reduced the risk of death by 54%.

MedPage Today also reported on a pair of Chinese trials, including the TAISHAN-302 study, which found that two investigational ADCs improved survival outcomes in patients with relapsed SCLC. However, further details of this study were not provided.

Brief written by urgent.news from MedPage Today, Medical Xpress — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.